Last reviewed · How we verify
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of decitabine and how well it works when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread to other places in the body. Androgen can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, may lessen the amount of androgen made by the body. Decitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving decitabine and enzalutamide may work better in treating participants with castration resistant prostate cancer.
Details
| Lead sponsor | Roswell Park Cancer Institute |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | WITHDRAWN |
| Start date | Thu Apr 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Apr 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma in the Soft Tissue
- Prostate Carcinoma Metastatic in the Bone
- PSA Level Greater Than or Equal to Two
- PSA Progression
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
Interventions
- Decitabine
- Enzalutamide
Countries
United States